Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank trimmed its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 32.3% in the third quarter, Holdings Channel reports. The firm owned 60,900 shares of the company’s stock after selling 29,118 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Neurocrine Biosciences were worth $7,017,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Tidal Investments LLC grew its position in shares of Neurocrine Biosciences by 57.8% during the 1st quarter. Tidal Investments LLC now owns 9,542 shares of the company’s stock valued at $1,316,000 after buying an additional 3,497 shares during the last quarter. Swedbank AB bought a new position in shares of Neurocrine Biosciences during the first quarter valued at approximately $1,933,000. GAMMA Investing LLC grew its holdings in shares of Neurocrine Biosciences by 34.1% during the second quarter. GAMMA Investing LLC now owns 1,553 shares of the company’s stock valued at $214,000 after purchasing an additional 395 shares during the last quarter. First Hawaiian Bank raised its position in shares of Neurocrine Biosciences by 6.2% during the 2nd quarter. First Hawaiian Bank now owns 5,483 shares of the company’s stock worth $755,000 after purchasing an additional 320 shares during the period. Finally, Massmutual Trust Co. FSB ADV lifted its holdings in shares of Neurocrine Biosciences by 43.4% in the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 512 shares of the company’s stock worth $70,000 after purchasing an additional 155 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Up 0.1 %

Shares of NBIX stock opened at $126.75 on Monday. The stock has a 50-day simple moving average of $119.26 and a 200 day simple moving average of $131.48. The stock has a market capitalization of $12.83 billion, a P/E ratio of 33.98 and a beta of 0.35. Neurocrine Biosciences, Inc. has a fifty-two week low of $110.95 and a fifty-two week high of $157.98.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. JPMorgan Chase & Co. upped their price objective on Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Raymond James restated an “outperform” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. HC Wainwright reiterated a “buy” rating and issued a $190.00 price objective on shares of Neurocrine Biosciences in a research report on Friday, November 1st. Barclays decreased their target price on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Finally, Royal Bank of Canada cut their price target on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a report on Friday, October 4th. Five research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.